Inhibition of puerarin on sodium-dependent glucose cotransporters 2 to promote urinary glucose excretion
10.7501/j.issn.1674-6376.2017.10.008
- VernacularTitle:葛根素抑制钠-葡萄糖协同转运蛋白2活性发挥促尿糖作用研究
- Author:
heng Yong SHI
1
;
ying Ying DENG
;
ping Ji LIU
;
hu En ZHANG
Author Information
1. 陕西中医药大学药学院
- Keywords:
puerarin;
sodium-dependent glucose cotransporters 2;
molecular docking;
oral glucose tolerance test (OGTT);
Urine glucose excretion test (UGE);
dapagliflozin
- From:
Drug Evaluation Research
2017;40(10):1408-1413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study that puerarin can prevent the renal glucose reabsorbtion process and promote urinary glucose excretion by inhibiting sodium-dependent glucose cotransporters 2 (SGLT2) to reduce plasma glucose in diabetes rats.Methods Molecular docking was carried out on puerarin and the obtained SGLT2 complexes through homology modeling method with dapagliflozin as positive control.Chinese hamster ovary (CHO) cells stably expressing human SGLT2 and [14C]-MethylD-glucopyranoside ([14C]-AMG) as the substrate were used in vitro for the transport assays and IC50 for SGLT2.The antihyperglycemic activity ofpuerarin was operated by oral glucose tolerance test (OGTT) and urinary glucose excretion (UGE) test in rats.Results Puerarin was identified as the substrate of SGLT2 through molecular docking,but the overall effect was not as strong asdapagliflozin.In vitro experiments showed that puerarin can strongly inhibit hSGLT2,the maximum effect was about 84％ with the half inhibitory concentration (IC50) of 0.40 mol/L.OGTT results showed that glucose inhibition rates of puerarin 10,30,60 and 120 mg/kg doses were 5.1％,6.5％,16％,and 22％ respectively,in a dose-dependent manner.In the UGE experiment,the urine sugar increased with the increase of puerarin dose.Compared with model group,the 30,60,and 120 mg/kg dose groups had significant difference (P ＜ 0.05 and 0.01).Conclusion Puerarin exhibited antiglycemic activity through inhibiting SGLT2 and was considered to be a new lead compound of SGLT2 inhibitors.
